Ibogaine treatment is not available inside the United States. The Drug Enforcement Administration classified ibogaine as a Schedule I controlled substance in 1970 — the same category as heroin. No licensed US prescriber can offer it. No pharmacy can dispense it. No treatment centre can administer it outside a federally approved clinical trial. Americans who seek ibogaine treatment access it abroad — primarily in Canada or Mexico.
Ibogaine is a Schedule I controlled substance in the United States — unavailable at any domestic clinic, hospital, or treatment programme since 1970. Americans who pursue ibogaine treatment access it in Canada, Mexico, or other countries where it is unscheduled or explicitly legal. Canada does not list ibogaine under the Controlled Drugs and Substances Act.
Why Ibogaine Is Unavailable Inside the US
The Controlled Substances Act passed in 1970. Ibogaine was placed in Schedule I alongside heroin — a category that denotes high potential for abuse and no accepted medical use. This happened before any peer-reviewed clinical research on ibogaine's therapeutic applications existed. Howard Lotsof first documented its effect on opioid withdrawal in 1962 and filed US patents for its use in addiction treatment in 1985 — fifteen years after the scheduling decision was already made.
Schedule I status means three things in practice: no licensed US prescriber can offer ibogaine, no pharmacy can dispense it, and no treatment centre can administer it outside a federally supervised clinical trial. The classification has not changed despite the research that now exists.
The fact that ibogaine research has been constrained by scheduling law for over 50 years is a policy failure, not a scientific verdict. The evidence that has accumulated despite those constraints is consistent enough in direction that multiple US states have now allocated institutional funding. That changes what may be available in five to ten years. It does not change what is available today.
Two narrow pathways within the US exist as of 2026. The April 2026 presidential executive order directs federal agencies to establish access pathways for psychedelic medicines, including ibogaine, under the Right to Try framework. FDA-supervised clinical trials offer access under research protocols. Neither of these functions as accessible treatment for most people seeking ibogaine for addiction, PTSD, or depression. Clinical trial enrollment requires meeting specific eligibility criteria, geographic proximity to a trial site, and timelines measured in months — not days.
Where Americans Access Ibogaine Treatment
The two primary destinations are Mexico and Canada.
Mexicohas no explicit prohibition on ibogaine. Clinics operate openly in Tijuana, Cancun, and Puerto Vallarta. Programmes cost $4,000–$12,000 USD. That spread reflects what is and is not present in each programme: at the low end, providers routinely omit the on-site physician, continuous cardiac monitoring, and emergency protocols that the peer-reviewed literature identifies as non-negotiable safety requirements. Mexico's ibogaine market is largely unregulated. Legal status does not substitute for medical infrastructure.
Canada does not list ibogaine under the Controlled Drugs and Substances Act. It is not explicitly prohibited — a meaningfully different legal position from the US Schedule I or the UK Class A classification. Providers in British Columbia and elsewhere operate under this framework.
Vancouver, BC sits 45 minutes by car from the Peace Arch border crossing. For Americans in Washington, Oregon, or Idaho, this is the most geographically accessible option. At Transcend, iboga ceremony costs $2,000–$5,000 CAD — approximately $1,500–$3,700 USD — including an on-site medical professional, cardiac monitoring throughout the ceremony, medicine, and facilitation.
A provider who does not require your EKG results and full medication list before accepting your application is not screening. They are accepting. The distinction matters — because the cardiac contraindications for ibogaine are the ones that have killed people when missed.
For a comparison of how Canadian providers differ from the Mexican market, the ibogaine treatment cost in Mexico guide covers the safety infrastructure gap in detail.
What US Research Is Now Doing
The 2023 Stanford study, published in Nature Medicine, treated 30 special operations veterans with treatment-resistant PTSD, traumatic brain injury, and depression. One month after ibogaine administration, researchers measured an 88% average reduction in PTSD symptoms, 87% in depression, and 81% in anxiety. These were people who had already tried conventional care without adequate response.
Special operations veterans are not, as a population, people who enter things naively. Many had been through VA programmes, medication protocols, and years of conventional treatment before this study. The scepticism they brought is part of what makes the findings worth noting — the results were not produced by expectation.
Following the Stanford study, Texas committed $50 million to clinical ibogaine trials at UTMB, UTHealth Houston, Texas A&M University, and Baylor University. Colorado established five ibogaine research sites in 2026. A presidential executive order in April 2026 directed federal agencies to accelerate research across psychedelic medicines.
The important distinction: these are research processes, not treatment programmes. Clinical trials require specific eligibility criteria and enrollment timelines that do not accommodate urgent need. Someone actively managing opioid dependence, severe PTSD, or treatment-resistant depression cannot wait for a trial that may or may not have available slots in a city that may or may not be accessible. The most direct path to treatment, for most Americans today, remains traveling outside the country.
For a detailed breakdown of what the Stanford study found and what it does not establish, read the Stanford ibogaine study guide.
The Medical Requirements Are the Same Everywhere
Wherever ibogaine is administered, specific screening requirements apply. These are not administrative preferences. They reflect specific physiological risks that ibogaine presents, and bypassing them has produced fatalities.
Required before any ceremony:
- EKG and cardiovascular assessment. Ibogaine prolongs the QT interval — the electrical recovery phase of the heartbeat. QT prolongation, significant arrhythmia, or recent myocardial infarction are absolute contraindications. An EKG identifies these before ceremony. Any provider that does not require one before accepting a participant is not operating safely.
- Blood panel. Liver function (ALT, AST, bilirubin), kidney function (creatinine, GFR), and complete blood count. Ibogaine is metabolised hepatically — compromised liver function alters clearance and amplifies risk.
- Complete medication review. SSRIs and SNRIs require a supervised taper before ceremony. The interaction risk is serotonin syndrome — potentially fatal in severe cases. Methadone requires a specific transition protocol. Lithium and most antipsychotics require careful review by the prescribing physician.
- Full medical and psychiatric history.
These requirements are identical in Vancouver, Tijuana, Lisbon, and everywhere else. What differs between providers is not whether the requirement exists — it is whether they enforce it. A provider that accepts applications without a mandatory EKG is not screening.
For the full list of screening requirements and what each identifies, the ibogaine contraindications guide covers each in detail.
Who This Is Not For
Ibogaine treatment is not appropriate for everyone who seeks it — including some people who want it very much.
Absolute contraindications:
- QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction
- Severe liver or kidney disease
- Active psychosis or schizophrenia spectrum disorder
- Pregnancy
- Current SSRI or SNRI use without a completed supervised taper
- Methadone without a specific transition protocol in place
- Lithium and most antipsychotic medications
Someone in acute psychiatric crisis is not an appropriate candidate. The medicine amplifies what is present, not what a person hopes to find. Entering ibogaine in a state of acute psychiatric instability does not produce stability — it produces an amplified version of that instability over 12–24 hours.
Someone primarily seeking a change of state, insight without sustained effort, or something to report back is also not an appropriate candidate. The medicine does not accommodate this approach. It tends to show people what they have been avoiding. For people who have not done sustained work on what underlies the problem they want addressed, this is usually confrontational rather than clarifying.
The screening conversation that ends in “this is not the right path for you at this moment” is one of the most important things any legitimate provider does. Providers who will find a way to proceed regardless of what screening shows are not doing anyone a favour.
Is This Right for You?
The question is not about logistics. It is about whether you are an appropriate candidate — and that requires honest answers to specific medical and psychiatric questions.
At Transcend in Vancouver, every application receives a personal response within 2–3 business days. If screening identifies a contraindication, you will be told — directly, without softening it. A conversation that ends in a no is not a rejection. It is accurate information that most providers in this field will not deliver.
For US residents with opioid dependence, treatment-resistant PTSD, or depression that has not responded adequately to conventional care — and who have no cardiac contraindications, no active SSRI use, and no history of acute psychosis — the screening conversation is the right next step.
Read more about what the ceremony involves, review the FAQ for the most common screening and preparation questions, or apply directly. If you are thinking about what comes after the ceremony — the integration work that determines whether anything lasting results — the integration page covers that specifically.
For the full history of ibogaine's US legal status, the guide to why ibogaine is illegal in the US covers the scheduling timeline in detail.